Drug
Cpx 351
Cpx 351: highest development phase Phase 2, developed by Jazz Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| CPX-351 NCT02269579 | Phase 2 | Acute Myeloid Leukemia (AML) |
| CPX-351 NCT03335267 | Phase 2 | Leukemia, Myeloid, Acute |
| CPX-351 NCT05656248 | Phase 2 | Myeloid Neoplasm |
| CPX-351 NCT03555955 | Phase 1 | Hematologic Malignancy |
| CPX-351 NCT00875693 | Phase 1 | Acute Myelogenous Leukemia |
Latest
No recent events.
Follow Cpx 351 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.